Stockreport

Lilly Canada remains steadfast in commitment to access options for patients amidst controversial CDA-AMC recommendation for Ebglyss™ (lebrikizumab) [Yahoo! Finance]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Final Recommendation for Ebglyss™ (lebrikizumab), published on Friday, November 15, 2024 . The CDA-AMC recommended that Ebglyss not be reimbursed by public drug plans, e [Read more]